Topicals represent 5.1% of total prescriptions and 14% of total drug cost, and are being prescribed as an alternative to some oral medications. Within this class, cost drivers including prescription (Rx) and private label topical analgesics (PLTAs) are associated with limited clinical efficacy and exorbitant pricing that often eliminates them as a favorable first-line therapy option. These and other challenges call for careful oversight that includes identification, clinical review and intervention, and/or recommendation of therapeutic alternatives where appropriate to help control inappropriate utilization and spend. Watch the video blog to learn more.
More stories
Workers' Comp
Article
Specialty Solutions Spotlight: Using Quality Physical Therapy First for Low Back Pain Helps Reduce Costs and Improves Outcomes
Should an MRI be the first step in addressing work-related lower back pain injuries?The U.S.
Workers' Comp
News Release
Enlyte Announces Its 2024 Heart of Case Management Award Winners
Honorees represent the best of those who make a profound impact on the lives of employees with injuries and disabilitiesS
WorkCompCentral
In the News
Enlyte Launches Physical Medicine Network
Business Insurance
In the News
Enlyte launches specialty service for injured workers
Workers' Comp
News Release
Enlyte Launches Apricus Physical Medicine, Offering End-to-End Specialty Service Solution for Industry
New program introduces comprehensive rehabilitative services with integrated clinical oversight and continuous care coordination
Auto Casualty
Article
Balanced Regulatory Environment: A Key Component to Unlocking the Value of Specialty Bill Review
Without the use of Specialty Bill Review (SBR), payers risk paying for errors or abuses created by providers with problematic billing practices.